Nicorandil/ morphine crosstalk accounts for antinociception and hepatoprotection in hepatic fibrosis in rats: Distinct roles of opioid/cGMP and NO/KATP pathways

Bedair, Asser F.; Wahid, Ahmed; El–Mezayen, Nesrine S.; El-Yazbi, Amira F.; Khalil, Hadeel A.; Hassan, Nayera W.; Afify, Elham A.

doi:10.1016/j.biopha.2023.115068

Cited by 3 publications

(1 citation statement)

References 119 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The selection of the current nicorandil dose was based on previous studies that utilized oral nicorandil treatment for rat models at a dose of 15 mg·kg −1 across various study durations (Abd El‐Azeem et al, 2023; Bedair, Wahid, El‐Mezayen, & Afify, 2023; Bedair, Wahid, el‐Mezayen, el‐Yazbi, et al, 2023; Liu et al, 2021).…”

Section: Methodsmentioning

confidence: 99%

Nicorandil mitigates arsenic trioxide‐induced lung injury via modulating vital signalling pathways SIRT1/PGC‐1α/TFAM, JAK1/STAT3, and miRNA‐132 expression

Abdel‐Wahab,

Zafaar,

Habeeb

et al. 2024

British J Pharmacology

View full text Add to dashboard Cite

Background and PurposeNicorandil, a selective opener of potassium channels, used to treat angina, has drawn attention for its potential in mitigating lung injury, positioning it as a promising therapeutic approach to treat drug‐induced lung toxicity. This study aimed to explore the protective role of nicorandil in arsenic trioxide (ATO)‐induced lung injury and to elucidate the underlying mechanistic pathways.Experimental ApproachWe assessed the effects of nicorandil (15 mg·kg−1, p.o.) in a rat model of pulmonary injury induced by ATO (5 mg·kg−1, i.p.). The assessment included oxidative stress biomarkers, inflammatory cytokine levels, and other biomarkers, including sirtuin‐1, sirtuin‐3, STAT3, TFAM, and JAK in lung tissue. Histological examination using H&E staining and molecular investigations using western blotting and PCR techniques were conducted.Key ResultsIn our model of lung injury, treatment with nicorandil ameliorated pathological changes as seen with H&E staining, reduced tissue levels of toxicity markers, and exerted significant antioxidant and anti‐inflammatory actions. On a molecular level, treatment with nicorandil down‐regulated JAK, STAT3, PPARγ, Nrf2, VEGF, p53, and micro‐RNA 132 while up‐regulating Sirt1, 3, TFAM, AMPK, and ERR‐α in lung tissue.Conclusions and ImplicationsThe results presented here show nicorandil as a significant agent in attenuating lung injury induced by ATO in a rodent model. Nonetheless, further clinical studies are warranted to strengthen these findings.

show abstract